StockNews.com Downgrades Inogen (NASDAQ:INGN) to Hold

Inogen (NASDAQ:INGN) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

Separately, Needham & Company LLC restated a “hold” rating on shares of Inogen in a research report on Friday, November 8th.

Inogen Trading Up 1.8 %

NASDAQ INGN opened at $9.38 on Thursday. The company has a 50-day moving average price of $9.66 and a two-hundred day moving average price of $9.58. Inogen has a 52 week low of $4.93 and a 52 week high of $13.33. The stock has a market cap of $223.41 million, a price-to-earnings ratio of -3.87 and a beta of 1.04.

Institutional Investors Weigh In On Inogen

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in Inogen by 4.9% in the 1st quarter. Vanguard Group Inc. now owns 1,424,026 shares of the medical technology company’s stock valued at $11,492,000 after acquiring an additional 65,954 shares during the last quarter. Pitcairn Co. bought a new stake in shares of Inogen in the 1st quarter worth approximately $86,000. Brown Capital Management LLC lifted its stake in Inogen by 26.6% during the first quarter. Brown Capital Management LLC now owns 1,975,312 shares of the medical technology company’s stock valued at $15,941,000 after purchasing an additional 414,903 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Inogen by 5.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 23,868 shares of the medical technology company’s stock worth $193,000 after buying an additional 1,188 shares in the last quarter. Finally, Stokes Family Office LLC boosted its holdings in Inogen by 162.1% during the second quarter. Stokes Family Office LLC now owns 113,985 shares of the medical technology company’s stock worth $927,000 after buying an additional 70,500 shares in the last quarter. 89.94% of the stock is currently owned by institutional investors and hedge funds.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.